Science Pool

Interesed in Evotec's Translational Molecular Patient Database? 

In this presentation, first presented at our luncheon during German Biotechnology Days, focuses on:

• The database's over 200,000 samples and data from over 15,000 patients
• Data-driven approaches for better diagnoses
• Categorization by disease mechanisms

View the presentation to learn more!

LEARN MORE

Learn more about our activities for Deep Proteomics at Scale to Drive Biomarker Discovery.

To further boost Evotec’s high-throughput proteomics platform we have implemented the Proteograph™ platform from Seer, which enables automated and unbiased nanoparticle based protein enrichment for maximal proteomic insights.

DOWNLOAD

Huntington´s Disease (HD) is a hereditary neurodegenerative disorder that is caused by a mutation in the huntingtin gene (mHTT) leading to deposition of pathologic protein aggregates in the brain.

This paper focuses on:

• Visualization of mHTT aggregate expression by positron emission tomography (PET) in rodent HD model
• Utility of the previously described novel PET imaging ligand CHDI-180 for detection of mHTT in rodent and post-mortem human HD brain
• Ability of CHDI-180 to serve as functional response indicator for mHTT lowering therapies

GET THE PAPER

Learn more about Evotec's regulated LC/MS bioanalysis capabilities and expertise including:

• High quality service across all phases of pre-clinical and clinical drug development in compliance with GLP and GCP regulations
• More than 25 years of experience to perform LC/MS activities in a regulated environment
• Extensive bioanalytical method development expertise to meet the most demanding and challenging client needs
• Multidisciplinary collaboration enabling integrated solutions to accelerate the drug development process

DOWNLOAD

Learn more about Evotec’s polymerase chain reaction (PCR) services including:

• Therapeutic modalities
• Sample management capabilities
• PCR applications 
• Quantitative real time PCR (qPCR) and reverse transcription qPCR (RT-qPCR) applications, including copy number estimation assays, gene expression profiling and genotyping assaysRegulated PCR services

DOWNLOAD

Learn more about our ligand binding assays and how they can support biological drug testing in a regulated environment, including:

• Regulated bioanalysis
• Immunogenicity
• Immunotoxicity
• Biomarkers (safety and efficacy)
• Clinical Pathology
• Sample Management
• Additional activities

DOWNLOAD

This article forms a book chapter in Artificial Intelligence in Drug Design.

In this review article, we discuss the use of machine learning approaches in large omics studies

The chapter includes:

• an overview of the typical analysis of an omics dataset using machine learning
• demonstration of how to build a model predicting drug-induced liver injury (DILI) using transcriptomics data
• best practices and pitfalls to consider during initial data exploration and model training through to validation and analysis of the final model

LEARN MORE

Fireside Chat at BIO-Europe 2021

Evotec Chief Scientific Officer, Dr Cord Dohrmann, talks to Dr Hubert Birner, Managing Partner at TVM Capital Life Sciences, about how Evotec has built an impressive and innovative platform.

WATCH NOW

Mass spectrometry (MS)-based ubiquitinomics allows a system-level understanding of ubiquitin signalling. 

In this publication, we focus on:

• a background to ubiquitinome profiling
• presentation of a scalable and robust workflow for deep and precise in vivo ubiquitinome profiling using DIA-MS (data-independent acquisition mass spectrometry) and neural network based data processing
• comprehensive mapping of substrates of deubiquitinase USP7, an anticancer drug target known to regulate tumour suppressor p53
• application of the method including rapid mode of action profiling of candidate drugs targeting deubiquitinases or ubiquitin ligases 

LEARN MORE